Literature DB >> 3755652

Clinical anticancer pharmacology: some pharmacokinetic considerations.

V A Levin.   

Abstract

Mesh:

Substances:

Year:  1986        PMID: 3755652     DOI: 10.1016/0305-7372(86)90014-9

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  6 in total

Review 1.  Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy.

Authors:  M J Moore; C Erlichman
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

2.  Formation of DNA adducts and tumor growth delay following intratumoral administration of DTI-015.

Authors:  William J Bodell; Donald D Giannini; Saira Singh; Dennis Pietronigro; Victor A Levin
Journal:  J Neurooncol       Date:  2003-05       Impact factor: 4.130

3.  Pharmacokinetics of carboplatin after intraperitoneal administration.

Authors:  F Elferink; W J van der Vijgh; I Klein; W W ten Bokkel Huinink; R Dubbelman; J G McVie
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 4.  Polyamines in brain tumor therapy.

Authors:  E S Redgate; S Boggs; A Grudziak; M Deutsch
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

Review 5.  Pharmacokinetic drug interactions with anticancer drugs.

Authors:  P M Loadman; M C Bibby
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

6.  Cell killing action of cell cycle phase-non-specific antitumor agents is dependent on concentration--time product.

Authors:  S Ozawa; Y Sugiyama; Y Mitsuhashi; T Kobayashi; M Inaba
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.